A long-term Novo Nordisk A/S skeptic recommended buying shares of the Danish weight-loss drug maker nine years after starting ...

Shares of Novo Nordisk and Eli Lilly slipped in premarket trading Wednesday after Roche said it had landed a $5.3 billion ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...

The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Novo Nordisk announced launching a direct-to-patient online pharmacy NovoCare, offering a more than half-price cut for its ...

Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...

After years of calling obesity drug stocks overhyped, a top analyst now sees Novo Nordisk as a big opportunity.

Novo Nordisk is providing direct-to-patient delivery of Wegovy (semaglutide) through the NovoCare Pharmacy program.

Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...

Novo Nordisk's U.S.-listed shares fell Monday morning following the release of data for a new phase 3 clinical trial of its ...